Table 4.
Risk of disease recurrence according to Cox regression test.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | CI 95% | p | HR | CI 95% | p | |
| Male gender | 1.014 | 0.3–3.1 | 0.98 | |||
| No syndrome | 3.064 | 0.4–23.6 | 0.282 | |||
| GI-NET | 1.874 | 0.6–5.8 | 0.276 | |||
| Grading G2 | 6.578 | 2.0–21.8 | 0.002 | ns | ||
| Stage IIIB-IV | 105.304 | 1.0–10,718-1 | 0.048 | 105.154 | 2.1–3099.1 | <0.000001 |
| Low SSTR2A QS | 2.886 | 0.8–10.6 | 0.11 | |||
| Low IGF-1R QS | 9.893 | 1.3–76.2 | 0.028 | ns | ||
| High p-mTOR QS | 3.700 | 1.2–11.1 | 0.02 | ns | ||
HR: hazard ratio; CI: confidence interval; ns: not statistically significant; GI-NET: gastrointestinal primary NET (versus pancreatic NET); SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score.